Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Debt: 2020-2022

  • SAB Biotherapeutics' Total Debt was N/A to $541,644 in Q4 2022 from the same period last year, while for Dec 2022 it was $541,644, marking a year-over-year change of. This contributed to the annual value of $541,644 for FY2022, which is N/A change from last year.
  • Latest data reveals that SAB Biotherapeutics reported Total Debt of $541,644 as of Q4 2022, which was up 214.84% from $172,037 recorded in Q4 2020.
  • SAB Biotherapeutics' 5-year Total Debt high stood at $541,644 for Q4 2022, and its period low was $172,037 during Q4 2020.
  • Over the past 2 years, SAB Biotherapeutics' median Total Debt value was $356,840 (recorded in 2020), while the average stood at $356,840.